Sotera Health Company SHC
Set alert
16.44 USD -1.30 -7.36%
As of Nov 3, 1:39 PM ET
16.40 Day range 17.28
13.09 52-week range 19.85
- YTD
- -6.83%
- 1 year
- -1.05%
- Open
- 17.09
- Prev close
- 17.74
- Mkt cap
- 4.69B
- Vol
- 2.22M
- Avg vol
- 2.30M
- EPS
- 0.57
- P/E
- 28.84
- Div yield
- 0.00%
More statistics
- Low
- 16.40
- High
- 17.28
- Forward P/E
- 16.50
- Beta
- 1.93
- Short ratio
- 7.82
- Inst. own
- 101.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 18.52
- 200-d avg
- 17.00
- 1y target
- 22.61
3M chart
Events in this range
- Aug 6, 2026Earnings: 0.26; estimate 0.2389; surprise 8.83%
- Aug 7, 2026Rating: JP Morgan · Neutral → Neutral
- Aug 7, 2026Rating: Piper Sandler · Overweight → Overweight
- Aug 7, 2026Rating: Barclays · Overweight → Overweight
- Aug 7, 2026Rating: Citigroup · Buy → Buy
- Oct 14, 2026Downgrade: JP Morgan · Neutral → Underweight
- Nov 3, 2026Earnings: —; estimate 0.2687; surprise —%
Signals (18)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 3, 2026 | 4 hours ago |
| RSI: Oversold | Nov 3, 2026 | 4 hours ago |
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
Analyst view
Consensus: buy
Buy
Price target (mean) 22.61 +37.6% upside
Now 16.44
- Target (low)
- 17.00
- Target (mean)
- 22.61
- Target (high)
- 25.00
Ratings (0m) 10 8 buy · 1 hold · 1 sell
- Strong buy3
- Buy5
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.26864 | 0.26 – 0.27 | 0.26 | +3.3% | 319.88M | +2.8% | 10 |
| Next quarter | 0.27557 | 0.27 – 0.28 | 0.26 | +6.0% | 325.60M | +7.3% | 10 |
| Current year | 0.98383 | 0.978 – 0.99 | 0.86 | +14.4% | 1.25B | +7.2% | 10 |
| Next year | 1.07 | 1.03 – 1.13 | 0.98383 | +9.3% | 1.32B | +5.9% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | Downgrade | Neutral | Underweight |
| Aug 7, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Aug 7, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Jun 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 5, 2026 | Goldman Sachs | Initiated | Buy | Buy |
| May 6, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 24, 2026 | Citigroup | Maintained | Buy | Buy |
| Jan 9, 2026 | Piper Sandler | Upgrade | Neutral | Overweight |
| Dec 18, 2025 | William Blair | Initiated | — | Outperform |
| Nov 13, 2025 | BMO Capital | Initiated | — | Outperform |
| Nov 5, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 5, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 5, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Oct 2, 2025 | Barclays | Maintained | Overweight | Overweight |
| Jun 24, 2025 | Barclays | Maintained | Overweight | Overweight |
| May 5, 2025 | Goldman Sachs | Upgrade | Neutral | Buy |
| Apr 23, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Apr 10, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 28, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 18, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 21, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Nov 6, 2024 | Citigroup | Maintained | Buy | Buy |
| Aug 6, 2024 | Barclays | Maintained | Overweight | Overweight |
| Aug 6, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| May 21, 2024 | Piper Sandler | Initiated | — | Neutral |
| Apr 10, 2024 | Barclays | Maintained | Overweight | Overweight |
| Apr 3, 2024 | Citigroup | Upgrade | Neutral | Buy |
